Literature DB >> 11181985

Long-term benefits in self-reported health status of nasal continuous positive airway pressure therapy for obstructive sleep apnoea.

C Jenkinson1, R J Davies, R Mullins, J R Stradling.   

Abstract

Doubt has been expressed about the efficacy of nasal continuous positive airways pressure (NCPAP) therapy for sleep apnoea. Recent evidence from a randomized controlled trial of 1 month duration, suggested that NCPAP therapy can have a substantial impact on subjective and clinical outcomes in the short term, but data was not available to determine whether these effects were sustained over the long term. This study, an extension of the original trial, examined whether the beneficial impacts of NCPAP continued over the longer term. Patients were followed-up 1 month after being placed on active or sub-therapeutic NCPAP. They completed health status measures and a clinical test of sleepiness. After this period, all patients were placed on NCPAP and followed up 5 months later. The beneficial impact of NCPAP on sleep apnoea was sustained on all measures at follow-up. Furthermore, those who had initially been in the sub-therapeutic arm gained scores after 5 months of NCPAP similar to those of the active group. The impact of NCPAP appears sustained in the longer term. Subjective health status instruments have been advocated as important outcome points in randomized trials. This study would support such a use, and shows the important role of patient report in the evaluation of health care.

Entities:  

Mesh:

Year:  2001        PMID: 11181985     DOI: 10.1093/qjmed/94.2.95

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  9 in total

1.  Comparison of three ways to determine and deliver pressure during nasal CPAP therapy for obstructive sleep apnoea.

Authors:  S D West; D R Jones; J R Stradling
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

Review 2.  Pathophysiology & genetics of obstructive sleep apnoea.

Authors:  Lisa Campana; Danny J Eckert; Sanjay R Patel; Atul Malhotra
Journal:  Indian J Med Res       Date:  2010-02       Impact factor: 2.375

3.  Reliability and validity of the Norwegian version of the Functional Outcomes of Sleep Questionnaire.

Authors:  Knut Stavem; Frank N Kjelsberg; Espen A Ruud
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

4.  Effects of continuous positive airway pressure on quality of life in patients with moderate to severe obstructive sleep apnea: data from a randomized controlled trial.

Authors:  Massimiliano M Siccoli; Justin C T Pepperell; Malcolm Kohler; Sonya E Craig; Robert J O Davies; John R Stradling
Journal:  Sleep       Date:  2008-11       Impact factor: 5.849

5.  Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.

Authors:  Yuichi Inoue; Yuji Takasaki; Yoshihiro Yamashiro
Journal:  J Clin Sleep Med       Date:  2013-08-15       Impact factor: 4.062

Review 6.  Obstructive sleep apnoea in the elderly: recognition and management considerations.

Authors:  Timothy G Quinnell; Ian E Smith
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Reconsidering first-line treatment for obstructive sleep apnea: a systematic review of the literature.

Authors:  Brian W Rotenberg; Claudio Vicini; Edward B Pang; Kenny P Pang
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-04-06

Review 8.  Trends in CPAP adherence over twenty years of data collection: a flattened curve.

Authors:  Brian W Rotenberg; Dorian Murariu; Kenny P Pang
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-08-19

9.  Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy.

Authors:  Paula K Schweitzer; Kingman P Strohl; Geert Mayer; Russell Rosenberg; Patricia Chandler; Michelle Baladi; Lawrence Lee; Atul Malhotra
Journal:  J Clin Sleep Med       Date:  2021-04-01       Impact factor: 4.062

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.